Systemic immune changes accompany combination treatment with immunotoxin LMB‐100 and nab‐paclitaxel
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5290
Abstract: LMB‐100 is a novel immune‐conjugate (immunotoxin) that targets mesothelin. A phase 1/2 clinical trial was conducted (NCT02810418) with primary objectives assessing the safety and efficacy of LMB‐100 ± nab‐paclitaxel. Participant blood samples were analyzed for changes in… read more here.
Keywords: lmb 100; 100 nab; combination; systemic immune ... See more keywords